文献速递其他结缔组织病

基于症状的原发性干燥综合征患者分层:国际观察队列的多维特征描述与随机临床试验再分析

Symptom-based stratification of patients with primary Sjögren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials.
PubMed 文献 · Lancet Rheumatol · 2019-09-25

该研究利用分层聚类分析,基于疼痛、疲劳、干燥、焦虑和抑郁五种常见症状,在英国原发性干燥综合征注册队列(n=608)中识别出四个亚组,并在挪威和法国独立验证队列(n=396)中确认。亚组间在外周血淋巴细胞计数、自身抗体阳性率及血清标志物等方面存在显著差异,且再分析两项3期临床试验提示不同亚组对羟氯喹和利妥昔单抗的治疗反应存在差异。

要点

  • 基于五种患者报告症状可将原发性干燥综合征分为四个亚组。
  • 亚组间存在外周血免疫细胞、自身抗体及细胞因子等病理生物学差异。
  • 再分析提示羟氯喹对高症状负担亚组、利妥昔单抗对干燥主导伴疲劳亚组可能有效。

核心结论

  • 基于患者报告症状的分层揭示了原发性干燥综合征不同的病理生物学内型,且对免疫调节治疗的反应存在差异。

研究设计与样本

  • 研究采用分层聚类分析,基于疼痛、疲劳、干燥、焦虑和抑郁五种症状,在英国原发性干燥综合征注册队列(UKPSSR,n=608)中识别亚组,并用多项逻辑回归确认。
  • 使用挪威和法国的两个独立验证队列(n=396)确认患者分层。
  • 对两项3期临床试验数据进行类似分层,评估不同亚组对羟氯喹和利妥昔单抗的治疗反应差异。

主要发现

  • 在UKPSSR队列中识别出四个亚组:低症状负担(LSB)、高症状负担(HSB)、干燥主导伴疲劳(DDF)和疼痛主导伴疲劳(PDF)。
  • 亚组间在外周血淋巴细胞计数、抗SSA和抗SSB抗体阳性率以及血清IgG、κ游离轻链、β2微球蛋白和CXCL13浓度方面存在显著差异,外周血转录组模块也存在差异表达。
  • 在独立验证队列(n=396)中观察到类似发现。
  • 再分析试验数据分层后提示,与安慰剂相比,HSB亚组对羟氯喹存在治疗效应,DDF亚组对利妥昔单抗存在治疗效应。

临床怎么用

  • 基于患者报告症状的分层方法可能有助于原发性干燥综合征的临床管理、试验设计和治疗开发。
  • 类似分层方法可能适用于其他慢性免疫介导疾病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Heterogeneity is a major obstacle to developing effective treatments for patients with primary Sjögren's syndrome. We aimed to develop a robust method for stratification, exploiting heterogeneity in patient-reported symptoms, and to relate these differences to pathobiology and therapeutic response. METHODS: We did hierarchical cluster analysis using five common symptoms associated with primary Sjögren's syndrome (pain, fatigue, dryness, anxiety, and depression), followed by multinomial logistic regression to identify subgroups in the UK Primary Sjögren's Syndrome Registry (UKPSSR). We assessed clinical and biological differences between these subgroups, including transcriptional differences in peripheral blood. Patients from two independent validation cohorts in Norway and France were used to confirm patient stratification. Data from two phase 3 clinical trials were similarly stratified to assess the differences between subgroups in treatment response to hydroxychloroquine and rituximab. FINDINGS: In the UKPSSR cohort (n=608), we identified four subgroups: Low symptom burden (LSB), high symptom burden (HSB), dryness dominant with fatigue (DDF), and pain dominant with fatigue (PDF). Significant differences in peripheral blood lymphocyte counts, anti-SSA and anti-SSB antibody positivity, as well as serum IgG, κ-free light chain, β2-microglobulin, and CXCL13 concentrations were observed between these subgroups, along with differentially expressed transcriptomic modules in peripheral blood. Similar findings were observed in the independent validation cohorts (n=396). Reanalysis of trial data stratifying patients into these subgroups suggested a treatment effect with hydroxychloroquine in the HSB subgroup and with rituximab in the DDF subgroup compared with placebo. INTERPRETATION: Stratification on the basis of patient-reported symptoms of patients with primary Sjögren's syndrome revealed distinct pathobiological endotypes with distinct responses to immunomodulatory treatments. Our data have important implications for clinical management, trial design, and therapeutic development. Similar stratification approaches might be useful for patients with other chronic immune-mediated diseases. FUNDING: UK Medical Research Council, British Sjogren's Syndrome Association, French Ministry of Health, Arthritis Research UK, Foundation for Research in Rheumatology. VIDEO ABSTRACT.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Tarn JR, Howard-Tripp N, Lendrem DW, et al. Symptom-based stratification of patients with primary Sjögren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. Lancet Rheumatol. 2019. PMID: 38229348. doi:10.1016/S2665-9913(19)30042-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。